Cancer Immunology, Immunotherapy

, Volume 53, Issue 8, pp 723–728 | Cite as

Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes

  • Jan Joseph
  • Bernd Niggemann
  • Kurt S. Zaenker
  • Frank Entschladen
Original Article

Abstract

Cell migration is of paramount importance in physiological processes such as immune surveillance, but also in the pathological processes of tumor cell migration and metastasis development. The factors that regulate this tumor cell migration, most prominently neurotransmitters, have thus been the focus of intense investigation. While the majority of neurotransmitters have a stimulatory effect on cell migration, we herein report the inhibitory effect of the endogenous substance anandamide on both tumor cell and lymphocyte migration. Using a collagen-based three-dimensional migration assay and time-lapse videomicroscopy, we have observed that the anandamide-mediated signals for CD8+ T lymphocytes and SW 480 colon carcinoma cells are each mediated by distinct cannabinoid receptors (CB-Rs). Using the specific agonist docosatetraenoylethanolamide (DEA), we have observed that the norepinephrine-induced migration of colon carcinoma cells is inhibited by the CB1-R. The SDF-1–induced migration of CD8+ T lymphocytes was, however, inhibited via the CB2-R, as shown by using the specific agonist JWH 133. Therefore, specific inhibition of tumor cell migration via CB1-R engagement might be a selective tool to prevent metastasis formation without depreciatory effects on the immune system of cancer patients.

Keywords

Anandamide Cannabinoid receptors Cell migration T lymphocytes Tumor cells 

Notes

Acknowledgements

This study was supported by the Fritz Bender Foundation, Munich, Germany, and the Bruno and Helene Joester Foundation, Cologne, Germany. We thank Beate Mainusch for excellent technical assistance and Theodore L. Drell IV for critical reading of the manuscript.

References

  1. 1.
    Barg J, Fride E, Hanus L, Levy R, Matus-Leibovitch N, Heldman E, Bayewitch M, Mechoulam R, Vogel Z (1995) Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. Eur J Pharmacol 287:145–152CrossRefPubMedGoogle Scholar
  2. 2.
    Behar TN, Smith SV, Kennedy RT, McKenzie JM, Maric I, Barker JL (2001) GABA(B) receptors mediate motility signals for migrating embryonic cortical cells. Cereb Cortex 11:744–753CrossRefPubMedGoogle Scholar
  3. 3.
    Berdyshev E, Boichot E, Corbel M, Germain N, Lagente V (1998) Effects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice. Life Sci 63:PL125–PL129Google Scholar
  4. 4.
    De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M, Di Marzo V (1998) The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci U S A 95:8375–8380CrossRefPubMedGoogle Scholar
  5. 5.
    De Petrocellis L, Melck D, Bisogno T, Di Marzo V (2000) Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chem Phys Lipids 108:191–209PubMedGoogle Scholar
  6. 6.
    Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605–613PubMedGoogle Scholar
  7. 7.
    Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946–1949PubMedGoogle Scholar
  8. 8.
    Drell TL 4th, Joseph J, Lang K, Niggemann B, Zaenker KS, Entschladen F (2003) Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 80:63–70CrossRefPubMedGoogle Scholar
  9. 9.
    Eason MG, Kurose H, Holt BD, Raymond JR, Liggett SB (1992) Simultaneous coupling of alpha 2-adrenergic receptors to two G-proteins with opposing effects: subtype-selective coupling of alpha 2C10, alpha 2C4, and alpha 2C2 adrenergic receptors to Gi and Gs. J Biol Chem 267:15795–15801PubMedGoogle Scholar
  10. 10.
    Entschladen F, Niggemann B, Zanker KS, Friedl P (1997) Differential requirement of protein tyrosine kinases and protein kinase C in the regulation of T cell locomotion in three-dimensional collagen matrices. J Immunol 159:3203–3210PubMedGoogle Scholar
  11. 11.
    Entschladen F, Gunzer M, Scheuffele CM, Niggemann B, Zanker KS (2000) T lymphocytes and neutrophil granulocytes differ in regulatory signaling and migratory dynamics with regard to spontaneous locomotion and chemotaxis. Cell Immunol 199:104–114CrossRefPubMedGoogle Scholar
  12. 12.
    Entschladen F, Lang K, Drell TL, Joseph J, Zaenker KS (2002) Neurotransmitters are regulators for the migration of tumor cells and leukocytes. Cancer Immunol Immunother 51:467–482CrossRefPubMedGoogle Scholar
  13. 13.
    Entschladen F, Drell TL 4th, Lang K, Joseph J, Zaenker KS (2004) Tumor cell migration, invasion and metastasis: navigation by neurotransmitters. Lancet Oncol 5:254–258Google Scholar
  14. 14.
    Friedl P, Noble PB, Zanker KS (1993) Lymphocyte locomotion in three-dimensional collagen gels: comparison of three quantitative methods for analysing cell trajectories. J Immunol Methods 165:157–165CrossRefPubMedGoogle Scholar
  15. 15.
    Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, Wiley JL, Martin BR (1999) 3-(1’,1’-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 7:2905–2914PubMedGoogle Scholar
  16. 16.
    Jorda MA, Rayman N, Valk P, De Wee E, Delwel R (2003) Identification, characterization, and function of a novel oncogene: the peripheral cannabinoid receptor Cb2. Ann N Y Acad Sci 996:10–16PubMedGoogle Scholar
  17. 17.
    Joseph J, Niggemann B, Zaenker KS, Entschladen F (2002) The neurotransmitter gamma-aminobutyric acid is an inhibitory regulator for the migration of SW 480 colon carcinoma cells. Cancer Res 62:6467–6469PubMedGoogle Scholar
  18. 18.
    Kaminski NE, Koh WS, Yang KH, Lee M, Kessler FK (1994) Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. Biochem Pharmacol 48:1899–1908PubMedGoogle Scholar
  19. 19.
    Kishimoto S, Gokoh M, Oka S, Muramatsu M, Kajiwara T, Waku K, Sugiura T (2003) 2-arachidonoylglycerol induces the migration of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanism. J Biol Chem 278:24469–24475CrossRefPubMedGoogle Scholar
  20. 20.
    Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, Friedman H (2003) The cannabinoid system and immune modulation. J Leukoc Biol 74:486–496CrossRefPubMedGoogle Scholar
  21. 21.
    Lang K, Niggemann B, Zanker KS, Entschladen F (2002) Signal processing in migrating T24 human bladder carcinoma cells: role of the autocrine interleukin-8 loop. Int J Cancer 99:673–680Google Scholar
  22. 22.
    Masur K, Niggemann B, Zanker KS, Entschladen F (2001) Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 61:2866–2869PubMedGoogle Scholar
  23. 23.
    Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561–564PubMedGoogle Scholar
  24. 24.
    Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M, Di Marzo V (2000) Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141:118–126PubMedGoogle Scholar
  25. 25.
    Mimeault M, Pommery N, Wattez N, Bailly C, Henichart JP (2003) Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 56:1–12CrossRefPubMedGoogle Scholar
  26. 26.
    Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50–56PubMedGoogle Scholar
  27. 27.
    Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61–65PubMedGoogle Scholar
  28. 28.
    Nong L, Newton C, Friedman H, Klein TW (2001) CB1 and CB2 receptor mRNA expression in human peripheral blood mononuclear cells (PBMC) from various donor types. Adv Exp Med Biol 493:229–233PubMedGoogle Scholar
  29. 29.
    Ortega A (2003) A new role for GABA: inhibition of tumor cell migration. Trends Pharmacol Sci 24:151–154CrossRefPubMedGoogle Scholar
  30. 30.
    Pertwee RG (1999) Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6:635–664PubMedGoogle Scholar
  31. 31.
    Roth MD, Baldwin GC, Tashkin DP (2002) Effects of delta-9-tetrahydrocannabinol on human immune function and host defense. Chem Phys Lipids 121:229–239CrossRefPubMedGoogle Scholar
  32. 32.
    Slipetz DM, O’Neill GP, Favreau L, Dufresne C, Gallant M, Gareau Y, Guay D, Labelle M, Metters KM (1995) Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol Pharmacol 48:352–361PubMedGoogle Scholar
  33. 33.
    Song ZH, Zhong M (2000) CB1 cannabinoid receptor-mediated cell migration. J Pharmacol Exp Ther 294:204–209PubMedGoogle Scholar
  34. 34.
    Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, Mackie K, Stella N (2003) Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23:1398–1405PubMedGoogle Scholar
  35. 35.
    Yuan M, Kiertscher SM, Cheng Q, Zoumalan R, Tashkin DP, Roth MD (2002) Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol 133:124–131CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Jan Joseph
    • 1
  • Bernd Niggemann
    • 1
  • Kurt S. Zaenker
    • 1
  • Frank Entschladen
    • 1
  1. 1.Institute of ImmunologyWitten/Herdecke UniversityWittenGermany

Personalised recommendations